159 related articles for article (PubMed ID: 24748380)
1. Quantitative proteomic analysis of oral brush biopsies identifies secretory leukocyte protease inhibitor as a promising, mechanism-based oral cancer biomarker.
Yang Y; Rhodus NL; Ondrey FG; Wuertz BR; Chen X; Zhu Y; Griffin TJ
PLoS One; 2014; 9(4):e95389. PubMed ID: 24748380
[TBL] [Abstract][Full Text] [Related]
2. Secretory leukocyte protease inhibitor (SLPI) expression and tumor invasion in oral squamous cell carcinoma.
Wen J; Nikitakis NG; Chaisuparat R; Greenwell-Wild T; Gliozzi M; Jin W; Adli A; Moutsopoulos N; Wu T; Warburton G; Wahl SM
Am J Pathol; 2011 Jun; 178(6):2866-78. PubMed ID: 21641406
[TBL] [Abstract][Full Text] [Related]
3. Secretory leukocyte peptidase inhibitor expression and apoptosis effect in oral leukoplakia and oral squamous cell carcinoma.
Wang X; Jin Y; Li YX; Yang Y
Oncol Rep; 2018 Apr; 39(4):1793-1804. PubMed ID: 29436667
[TBL] [Abstract][Full Text] [Related]
4. The relationship between secretory leukocyte protease inhibitor expression and Epstein-Barr virus status among patients with nasopharyngeal carcinoma.
Tse KP; Wu CS; Hsueh C; Chang KP; Hao SP; Chang YS; Tsang NM
Anticancer Res; 2012 Apr; 32(4):1299-307. PubMed ID: 22493362
[TBL] [Abstract][Full Text] [Related]
5. Nodal metastasis and survival in oral cancer: Association with protein expression of SLPI, not with LCN2, TACSTD2, or THBS2.
Noorlag R; van der Groep P; Leusink FK; van Hooff SR; Frank MH; Willems SM; van Es RJ
Head Neck; 2015 Aug; 37(8):1130-6. PubMed ID: 24764155
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the potential of a novel oral lesion exudate collection method coupled with mass spectrometry-based proteomics for oral cancer biomarker discovery.
Kooren JA; Rhodus NL; Tang C; Jagtap PD; Horrigan BJ; Griffin TJ
Clin Proteomics; 2011 Sep; 8(1):13. PubMed ID: 21914210
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus infection in head and neck cancer: the role of the secretory leukocyte protease inhibitor.
Hoffmann M; Quabius ES; Tribius S; Hebebrand L; Görögh T; Halec G; Kahn T; Hedderich J; Röcken C; Haag J; Waterboer T; Schmitt M; Giuliano AR; Kast WM
Oncol Rep; 2013 May; 29(5):1962-8. PubMed ID: 23467841
[TBL] [Abstract][Full Text] [Related]
8. Human uterus myoma and gene expression profiling: A novel in vitro model for studying secretory leukocyte protease inhibitor-mediated tumor invasion.
Mikami Y; Fukushima A; Komiyama Y; Iwase T; Tsuda H; Higuchi Y; Hayakawa S; Kuyama K; Komiyama K
Cancer Lett; 2016 Aug; 379(1):84-93. PubMed ID: 27238568
[TBL] [Abstract][Full Text] [Related]
9. Serum and salivary levels of chemerin and MMP-9 in oral squamous cell carcinoma and oral premalignant lesions.
Ghallab NA; Shaker OG
Clin Oral Investig; 2017 Apr; 21(3):937-947. PubMed ID: 27161218
[TBL] [Abstract][Full Text] [Related]
10. The expression and clinical significance of secretory leukocyte proteinase inhibitor (SLPI) in mammary carcinoma using bioinformatics analysis.
Xie W; Zhang H; Qin S; Zhang J; Fan X; Yin Y; Liang R; Long H; Yi W; Fu D; Ma C; Lv M; Yu F
Gene; 2019 Dec; 720():144088. PubMed ID: 31476404
[TBL] [Abstract][Full Text] [Related]
11. Salivary proteomics for oral cancer biomarker discovery.
Hu S; Arellano M; Boontheung P; Wang J; Zhou H; Jiang J; Elashoff D; Wei R; Loo JA; Wong DT
Clin Cancer Res; 2008 Oct; 14(19):6246-52. PubMed ID: 18829504
[TBL] [Abstract][Full Text] [Related]
12. Secretory leukocyte protease inhibitor regulates human periodontal ligament cell production of pro-inflammatory cytokines.
Svensson D; Aidoukovitch A; Anders E; Jönsson D; Nebel D; Nilsson BO
Inflamm Res; 2017 Sep; 66(9):823-831. PubMed ID: 28597116
[TBL] [Abstract][Full Text] [Related]
13. Expression of oral secretory leukocyte protease inhibitor in HIV-infected subjects with long-term use of antiretroviral therapy.
Nittayananta W; Kemapunmanus M; Yangngam S; Talungchit S; Sriplung H
J Oral Pathol Med; 2013 Mar; 42(3):208-15. PubMed ID: 23126266
[TBL] [Abstract][Full Text] [Related]
14. Salivary proteins from dysplastic leukoplakia and oral squamous cell carcinoma and their potential for early detection.
Sivadasan P; Gupta MK; Sathe G; Sudheendra HV; Sunny SP; Renu D; Hari PS; Gowda H; Suresh A; Kuriakose MA; Sirdeshmukh R
J Proteomics; 2020 Feb; 212():103574. PubMed ID: 31706945
[TBL] [Abstract][Full Text] [Related]
15. Expression of secretory leukocyte protease inhibitor in middle ear cholesteatoma.
Lee JK; Chae SW; Cho JG; Lee HM; Hwang SJ; Jung HH
Eur Arch Otorhinolaryngol; 2006 Dec; 263(12):1077-81. PubMed ID: 16868773
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of protease inhibitor-dead secretory leukocyte protease inhibitor causes more aggressive ovarian cancer in vitro and in vivo.
Devoogdt N; Rasool N; Hoskins E; Simpkins F; Tchabo N; Kohn EC
Cancer Sci; 2009 Mar; 100(3):434-40. PubMed ID: 19154415
[TBL] [Abstract][Full Text] [Related]
17. Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome.
Dickey BL; Sirak B; Martin-Gomez L; Reich RR; Abrahamsen M; Isaacs-Soriano K; Chung CH; Giuliano AR
PLoS One; 2021; 16(7):e0254161. PubMed ID: 34214131
[TBL] [Abstract][Full Text] [Related]
18. Secretory leukocyte protease inhibitor is associated with MMP-2 and MMP-9 to promote migration and invasion in SNU638 gastric cancer cells.
Choi BD; Jeong SJ; Wang G; Park JJ; Lim DS; Kim BH; Cho YI; Kim CS; Jeong MJ
Int J Mol Med; 2011 Oct; 28(4):527-34. PubMed ID: 21687932
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of a secretory leukocyte protease inhibitor in human gastric cancer.
Cheng WL; Wang CS; Huang YH; Liang Y; Lin PY; Hsueh C; Wu YC; Chen WJ; Yu CJ; Lin SR; Lin KH
Int J Cancer; 2008 Oct; 123(8):1787-96. PubMed ID: 18688858
[TBL] [Abstract][Full Text] [Related]
20. Secretory leukocyte protease inhibitor (SLPI) in cancer pathophysiology: Mechanisms of action and clinical implications.
Zhang X; Liu SS; Ma J; Qu W
Pathol Res Pract; 2023 Aug; 248():154633. PubMed ID: 37356220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
